Sironax
- Biotech or pharma, therapeutic R&D
Sironax focuses on age-related degenerative diseases. Leading assets include an allosteric, brain-penetrant CNS SARM1 inhibitor (Ph1), a brain-penetrant RIPK1 inhibitor (Ph2a), a NAMPT activator (IND enabling), and a differentiated brain delivery platform
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}